Search

Aluminum zirconium pentachlorohydrex gly

Aluminum zirconium pentachlorohydrex gly, or Aluminum Zirconium Tetrachlorohydrex Glycine, is commonly used as an antiperspirant in many deodorant products. … It is a coordination complex of Aluminum Zirconium pentachlorohydrate and glycine. Its anhydrous form allows the molecule to absorb moisture.

TGAAC94

The Health Recombinant DNA Advisory Committee (RAC) concluded that a possible role of the gene transfer in this clinical course could not definitively be excluded due to the lack of data. [A264038] … It was under investigation in clinical trials to treat Inflammatory Arthritis. In 2007, one patient participating in the clinical trial died and the trial was placed on clinical hold by the FDA.

Sinomenine

GnRH pharmaccine

The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation … The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".

MUC1 Dendritic Cell Vaccine

Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. … The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system

SQ-109

SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. … Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.

Rosabulin

Rosabulin has a monoisotopic molecular weight of 400.1 Da. … Rosabulin is under investigation in clinical trial NCT00276913 (A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors).

Crelosidenib

Crelosidenib has a monoisotopic molecular weight of 504.28 Da. … Crelosidenib is under investigation in clinical trial NCT04603001 (Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations).

DS-2325a

DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

Lifarizine

The usage of the INN stem '-rizine' in the name indicates that Lifarizine is a antihistaminic/cerebral (or peripheral) vasodilator. Lifarizine has a monoisotopic molecular weight of 436.26 Da.